Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Ipilimumab N01 +/- Lenvatinib +/- TACE/Ablation as Neoadjuvant Therapy for Resectable HCC
NCT07487662Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, ipilimumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Mar 2026; status: recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07487662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487662.